It was hypothesized that CHI3L1 may activate the ERK1/2 pathway through autocrine and paracrine effects, thereby driving the proliferation of CTCL cells and promoting disease progression. This evidence concerns the gene MAPK3 and primary cutaneous T-cell non-Hodgkin lymphoma.